News & Insights

• Biofidelity has closed a £17.3m Series A+ funding round led by led by Octopus Ventures and SBI Investment Co Ltd.
• The capital will be used to commercialise Biofidelity’s ASPYRE technology, a high sensitivity molecular diagnostic platform and the first assay for high sensitivity diagnosis of non-small-cell-lung-cancer. This is will include launch in North America.
• The funding will also be used to expand and validate Biofidelity’s technology platform on other key oncology applications where access to high sensitivity precision diagnostics is key to improving outcomes.

• ONI has closed a $75m Series B financing led by US investors ARCH Venture Partners and Casdin Capital.
• ONI is a pioneer in observing single molecules in living cells. The Company’s first product, the Nanoimager, is the world’s first desktop, super-resolution, single-molecule imaging platform capable of visualising and tracking individual molecules in complex systems such as nanoparticles, living cells and tissue with 20nm resolution.
• The Series B funds will be used to build a product portfolio that harnesses the Company’s innovative technology to unlock new possibilities in therapeutic and diagnostic development, as well as basic life sciences research.

• OrganOx Ltd. is commercialising the metra L, the world’s first normothermic liver perfusion device.
• OTIF’s investment was advised by Oxford Investment Consultants LLP and was part of a £6.4 million round led by Oxford Investment Consultants LLP.
• Funding will accelerate a number of programmes in OrganOx’s R&D pipeline, with a Phase I clinical trial for a normothermic kidney perfusion device due to start later this year.
• This investment in OrganOx Ltd., brings the total funds invested by OTIF in the Company to £5.6m.

• Oxford Endovascular Ltd is commercialising OxiFlow™, a novel blood flow diversion device (‘stent’) for treating Intracranial Aneurysms (ICAs).
• OTIF’s investment was advised by Oxford Investment Consultants LLP and was part of a $10m Series A funding round led by Vulpes Investment Management, a Singapore-based life sciences investor.
• This is the second OTIF investment in Oxford Endovascular to date, bringing total funds invested by the fund in the Company to £500k.

OIC portfolio company Oxehealth has secured financial commitments totalling £10m, which will be delivered in two rounds across 2021 and 2022.

The two rounds have been underwritten by existing shareholders, which included a commitment from the Oxford Technology & Innovations EIS Fund (OTIF) advised by OIC.